Risk of anaphylaxis in opioid dependent persons: Effects of heroin versus substitution substance

Substance Abuse: Treatment, Prevention, and Policy

Volumn 9, Issue 1, 2014, Pages

  Maurer, Ute ^a   Kager, Carola ^b   Fellinger, Christina ^b   Loader, Dagmara ^b   Pollesböck, Augustin ^c   Spitzer, Bernhard ^c   Jarisch, Reinhart ^b  

^a UNIVERSITY OF APPLIED SCIENCES WIENER NEUSTADT   (Austria)

^b FAZ Floridsdorf Allergy Center   (Austria)

^c Withdrawal Centre   (Austria)

Author keywords

Anaphylaxis; Drug addiction; Histamine; Opioid

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AMINE OXIDASE (COPPER CONTAINING); BIOLOGICAL MARKER; DIAMORPHINE; HISTAMINE; MORPHINE; TRYPTASE;

ADOLESCENT; ADULT; BLOOD; CASE CONTROL STUDY; COMPLICATION; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE; YOUNG ADULT;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ADULT; AMINE OXIDASE (COPPER-CONTAINING); BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DRUG HYPERSENSITIVITY; FEMALE; HEROIN; HISTAMINE; HUMANS; MALE; MIDDLE AGED; MORPHINE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE, INTRAVENOUS; TRYPTASES; YOUNG ADULT;

EID: 84897619389     PISSN: None     EISSN: 1747597X     Source Type: Journal    
DOI: 10.1186/1747-597X-9-12     Document Type: Article

References (60)

1. Risser D, Honigschnabl S, Stichenwirth M, Pfudl S, Sebald D, Kaff A, Bauer G. Mortality of opiate users in Vienna, Austria. Drug Alcohol Depend 2001, 64(3):251-256. 10.1016/S0376-8716(01)00131-4, 11672939.
2. Risser D, Schneider B. Drug-related deaths between 1985 and 1992 examined at the Institute of Forensic Medicine in Vienna, Austria. Addiction 1994, 89(7):851-857. 10.1111/j.1360-0443.1994.tb00988.x, 8081183.
3. Darke S, Zador D. Fatal heroin 'overdose': a review. Addiction 1996, 91(12):1765-1772. 10.1111/j.1360-0443.1996.tb03800.x, 8997759.
4. Staub C, Jeanmonod R, Fryc O. Morphine in postmortem blood: its importance for the diagnosis of deaths associated with opiate addiction. Int J Legal Med 1990, 104(1):39-42. 10.1007/BF01816482, 11453091.
5. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ 2013, 91(2):102-123. 10.2471/BLT.12.108282, 3605003, 23554523.
6. Polettini A, Poloni V, Groppi A, Stramesi C, Vignali C, Politi L, Montagna M. The role of cocaine in heroin-related deaths. Hypothesis on the interaction between heroin and cocaine. Forensic Sci Int 2005, 153(1):23-28. 10.1016/j.forsciint.2005.04.017, 16039419.
7. Simons FE. 9. Anaphylaxis. J Allergy Clin Immunol 2008, 121(2 Supp):S402-S407. quiz S420.
8. Simons FE. Anaphylaxis. J Allergy Clin Immunol 2010, 125(2 Suppl 2):S161-S181.
9. Simons FE. World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings. Ann Allergy Asthma Immunol 2010, 104(5):405-412. 10.1016/j.anai.2010.01.023, 20486330.
10. Ben-Shoshan M, Clarke AE. Anaphylaxis: past, present and future. Allergy 2011, 66(1):1-14.
11. Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction?. Curr Opin Allergy Clin Immunol 2004, 4(4):285-290. 10.1097/01.all.0000136762.89313.0b, 15238794.
12. Tsai MG, S G. Mast cells: effector cells of anaphylaxis. Anaphylaxis and Hypersensitivity Reactions 2011, 47-68. New York: Humana Press, Castells MC.
13. Lee JK, Vadas P. Anaphylaxis: mechanisms and management. Clin Exp Allergy 2011, 41(7):923-938. 10.1111/j.1365-2222.2011.03779.x, 21668816.
14. Stone SF, Cotterell C, Isbister GK, Holdgate A, Brown SG. Elevated serum cytokines during human anaphylaxis: identification of potential mediators of acute allergic reactions. J Allergy Clin Immunol 2009, 124(4):786-792. e784, 10.1016/j.jaci.2009.07.055, 19767073.
15. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2010, 125(2 Suppl 2):S73-S80. 2847274, 20176269.
16. Schwartz LB. Effector cells of anaphylaxis: mast cells and basophils. Novartis Found Symp 2004, 257:65-74. discussion 74-69, 98-100, 276-185.
17. Simons FE, Sampson HA. Anaphylaxis epidemic: fact or fiction?. J Allergy Clin Immunol 2008, 122(6):1166-1168. 10.1016/j.jaci.2008.10.019, 19084110.
18. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, Brown SG, Camargo CA, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006, 117(2):391-397. 10.1016/j.jaci.2005.12.1303, 16461139.
19. Sanz ML, Gamboa PM, Garcia-Figueroa BE, Ferrer M. In vitro Diagnosis of Anaphylaxis. Anaphylaxis Chemical Immunology and Allergy, Volume 95 2010, 125-140. Basel: Kager, Ring J.
20. Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 1989, 83(5):1551-1555. 10.1172/JCI114051, 303860, 2468689.
21. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006, 26(3):451-463. 10.1016/j.iac.2006.05.010, 16931288.
22. Baldo BA, Pham NH. Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two. Anaesth Intensive Care 2012, 40(2):216-235.
23. Veien M, Szlam F, Holden JT, Yamaguchi K, Denson DD, Levy JH. Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells. Anesthesiology 2000, 92(4):1074-1081. 10.1097/00000542-200004000-00026, 10754628.
24. Stellato C, Cirillo R, de Paulis A, Casolaro V, Patella V, Mastronardi P, Mazzarella B, Marone G. Human basophil/mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release. Anesthesiology 1992, 77(5):932-940. 10.1097/00000542-199211000-00016, 1280014.
25. Organization WH ICD-10, the ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. 1993, World Health Organization, Organization WH.
26. Union E. EU Drugs Strategy (2013-2020). 2012,
27. Dale HH, Laidlaw PP. The physiological action of beta-iminazolylethylamine. J Physiol 1910, 41(5):318-344. 1512903, 16993030.
28. Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol 2006, 147(Suppl 1):S127-S135. 1760721, 16402096.
29. Di Bello MG, Masini E, Ioannides C, Ndisang JF, Raspanti S, Bani Sacchi T, Mannaioni PF. Histamine release from rat mast cells induced by the metabolic activation of drugs of abuse into free radicals. Inflamm Res 1998, 47(3):122-130. 10.1007/s000110050299, 9562337.
30. Hermens JM, Ebertz JM, Hanifin JM, Hirshman CA. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology 1985, 62(2):124-129. 10.1097/00000542-198502000-00005, 2578752.
31. Immunotech BCC RIA Histamine, Immunradiometrischer Assay für die quantitative in vitro Bestimmung von Histamin in biologischen Proben. 1-18. Immunotech SAS, Immunotech BCC.
32. Jarisch R. Histamin-Intoleranz, Histamin und Seekrankheit. 2013, Stuttgart: Thieme Verlag.
33. Luk GD, Bayless TM, Baylin SB. Diamine oxidase (histaminase): a circulating marker for rat intestinal mucosal maturation and integrity. J Clin Invest 1980, 66(1):66-70. 10.1172/JCI109836, 371506, 6772669.
34. Raithel M, Ulrich P, Hochberger J, Hahn EG. Measurement of gut diamine oxidase activity. Diamine oxidase as a new biologic marker of colorectal proliferation?. Ann N Y Acad Sci 1998, 859:262-266. 10.1111/j.1749-6632.1998.tb11142.x, 9928401.
35. Mayer DE, Krauskopf A, Hemmer W, Moritz K, Jarisch R, Reiter C. Usefulness of post mortem determination of serum tryptase, histamine and diamine oxidase in the diagnosis of fatal anaphylaxis. Forensic Sci Int 2011, 212(1-3):96-101.
36. Diaminoxidase (DAO), Radioextraktionsassay (REA) zur quantitativen Bestimmung der DAO-Aktivität Serum und Plasma. [http://www.sciotec.at/en/products/diagnostics/].
37. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987, 316(26):1622-1626. 10.1056/NEJM198706253162603, 3295549.
38. Payne V, Kam PC. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia 2004, 59(7):695-703. 10.1111/j.1365-2044.2004.03757.x, 15200544.
39. Test Principle ImmunoCAP Tryptase. [http://www.phadia.com/da/Products/Allergy-testing-products/ImmunoCAP-Assays/ImmunoCAP-Tryptase/].
40. Dada N, Kim NW, Wolfert RL. Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn 2002, 2(1):17-22. 10.1586/14737159.2.1.17, 11963798.
41. Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn 2007, 7(5):511-517. 10.1586/14737159.7.5.511, 17892360.
42. Zalewski A, Nelson JJ, Hegg L, Macphee C. Lp-PLA2: a new kid on the block. Clin Chem 2006, 52(9):1645-1650. 10.1373/clinchem.2006.070672, 16873290.
43. The PLAC Test ELISA Kit. [http://www.plactest.com/international/package-insert-plac-test-elisa-kit].
44. Hirshman CA, Downes H, Butler S. Relevance of plasma histamine levels to hypotension. Anesthesiology 1982, 57(5):424-426. 10.1097/00000542-198211000-00018, 7137626.
45. Fahmy NR, Sunder N, Soter NA. Role of histamine in the hemodynamic and plasma catecholamine responses to morphine. Clin Pharmacol Ther 1983, 33(5):615-620. 10.1038/clpt.1983.83, 6839633.
46. Barke KE, Hough LB. Opiates, mast cells and histamine release. Life Sci 1993, 53(18):1391-1399. 10.1016/0024-3205(93)90581-M, 7694026.
47. Marone G, Stellato C, Mastronardi P, Mazzarella B. Mechanisms of activation of human mast cells and basophils by general anesthetic drugs. Annales francaises d'anesthesie et de reanimation 1993, 12(2):116-125.
48. Levy JH, Brister NW, Shearin A, Ziegler J, Hug CC, Adelson DM, Walker BF. Wheal and flare responses to opioids in humans. Anesthesiology 1989, 70(5):756-760. 10.1097/00000542-198905000-00008, 2470272.
49. Leysen J, De Witte L, Sabato V, Faber M, Hagendorens M, Bridts C, De Clerck L, Ebo D. IgE-mediated allergy to pholcodine and cross-reactivity to neuromuscular blocking agents: Lessons from flow cytometry. Cytometry B Clin Cytom 2013, 84(2):65-70.
50. Edston E, van Hage-Hamsten M. beta-Tryptase measurements post-mortem in anaphylactic deaths and in controls. Forensic Sci Int 1998, 93(2-3):135-142. 10.1016/S0379-0738(98)00040-1, 9717264.
51. Edston E, van Hage-Hamsten M. Anaphylactoid shock-a common cause of death in heroin addicts?. Allergy 1997, 52(9):950-954. 10.1111/j.1398-9995.1997.tb01256.x, 9298181.
52. Rook EJ, Hillebrand MJ, Rosing H, van Ree JM, Beijnen JH. The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 824(1-2):213-221.
53. Karasuyama H, Mukai K, Tsujimura Y, Obata K. Newly discovered roles for basophils: a neglected minority gains new respect. Nat Rev Immunol 2009, 9(1):9-13. 10.1038/nri2458, 19039320.
54. Mukai K, Obata K, Tsujimura Y, Karasuyama H. [The roles for basophils in allergy]. Nihon Rinsho 2009, 67(11):2095-2099.
55. Khuseyinova N, Imhof A, Rothenbacher D, Trischler G, Kuelb S, Scharnagl H, Maerz W, Brenner H, Koenig W. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 2005, 182(1):181-188. 10.1016/j.atherosclerosis.2004.10.046, 16115490.
56. Haemmig RB, Tschacher W. Effects of high-dose heroin versus morphine in intravenous drug users: a randomised double-blind crossover study. J Psychoactive Drugs 2001, 33(2):105-110. 10.1080/02791072.2001.10400475, 11476257.
57. Grossmann M, Abiose A, Tangphao O, Blaschke TF, Hoffman BB. Morphine-induced venodilation in humans. Clin Pharmacol Ther 1996, 60(5):554-560. 10.1016/S0009-9236(96)90151-4, 8941028.
58. Schug SA, Zech D, Grond S. Adverse effects of systemic opioid analgesics. Drug Saf 1992, 7(3):200-213. 10.2165/00002018-199207030-00005, 1354445.
59. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378(9791):571-583. 10.1016/S0140-6736(11)61097-0, 3285467, 21802134.
60. Eskild A, Magnus P, Samuelsen SO, Sohlberg C, Kittelsen P. Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users. Int J Epidemiol 1993, 22(2):315-320. 10.1093/ije/22.2.315, 8505190.